Abstract

Tacrolimus is a first-line immunosuppressant to reduce the incidence of graft rejection after kidney transplantation, which may potentially interact with various drugs, resulting in altered blood concentrations. Caspofungin, an echinocandin antifungal agent, is frequently co-administered with tacrolimus to treat fungal infections in kidney transplant patients. The previously published article titled "Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different CYP3A5 genotypes" provides a concise review, focusing specifically on CYP3A5 genotypes affect the interaction between tacrolimus and caspofungin. A thorough understanding of drug interactions is critical for optimizing immunosuppressive therapy, reducing adverse drug reactions, and ultimately achieving more effective individualized dosing for kidney transplant patients.

Keywords: Tacrolimus; Caspofungin; CYP3A5; Drug-drug interactions; Kidney transplantation